Neuren Pharma tumbles 14pc on short-seller report
NEW YORK: Neuren Pharmaceuticals has rebuked a short seller report targeting its US-listed drug licensing
NEW YORK: Neuren Pharmaceuticals has rebuked a short seller report targeting its US-listed drug licensing